[go: up one dir, main page]

ZA965368B - A pharmaceutical formulation - Google Patents

A pharmaceutical formulation

Info

Publication number
ZA965368B
ZA965368B ZA965368A ZA965368A ZA965368B ZA 965368 B ZA965368 B ZA 965368B ZA 965368 A ZA965368 A ZA 965368A ZA 965368 A ZA965368 A ZA 965368A ZA 965368 B ZA965368 B ZA 965368B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
ZA965368A
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmega Soerensen
Ole Hvilsted Olsen
Lars Thim
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA965368B publication Critical patent/ZA965368B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA965368A 1995-07-14 1996-06-25 A pharmaceutical formulation ZA965368B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14

Publications (1)

Publication Number Publication Date
ZA965368B true ZA965368B (en) 1997-01-14

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965368A ZA965368B (en) 1995-07-14 1996-06-25 A pharmaceutical formulation

Country Status (14)

Country Link
EP (1) EP0839049A1 (en)
JP (1) JPH11509212A (en)
KR (1) KR19990028981A (en)
CN (1) CN1190897A (en)
AU (1) AU715997B2 (en)
BR (1) BR9609741A (en)
CA (1) CA2226523A1 (en)
CZ (1) CZ9498A3 (en)
HU (1) HUP9802287A3 (en)
IL (1) IL122583A0 (en)
NO (1) NO980155D0 (en)
PL (1) PL324379A1 (en)
WO (1) WO1997003692A1 (en)
ZA (1) ZA965368B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1076703B2 (en) 1998-05-15 2010-12-15 Genentech, Inc. Therapeutic uses of il-17 homologous polypeptides
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
WO2001051635A2 (en) 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
DE60043322D1 (en) 1999-06-15 2009-12-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids for their coding
EP1669371A3 (en) 1999-12-01 2006-06-21 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP1897945B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
KR20090007504A (en) 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 Non-aqueous injections for the sustained release of somatotropin
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
AU4935701A (en) 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR20030023878A (en) 2000-06-26 2003-03-20 몬산토 테크놀로지 엘엘씨 Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
AU2001281113B2 (en) 2000-08-07 2006-07-20 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK1485477T3 (en) 2002-02-25 2009-08-10 Genentech Inc New type 1 cytokine receptor GLM-R
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
KR101148657B1 (en) 2003-06-06 2012-07-05 제넨테크, 인크. Modulating the interaction between hgf beta chain and c-met
PL1641822T3 (en) 2003-07-08 2013-10-31 Genentech Inc Heterologous IL-17 A / F polypeptides and their therapeutic applications
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
ES2326670T3 (en) 2004-03-30 2009-10-16 Nsgene A/S THERAPEUTIC USE OF THE NSG33 GROWTH FACTOR.
MX2007004676A (en) 2004-10-27 2007-11-14 Univ Denver Adrenocorticotropic hormone analogs and related methods.
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP2322552B1 (en) 2005-06-21 2016-02-10 Xoma (Us) Llc IL-1beta binding antibodies and fragments thereof
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
JP2009504183A (en) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド Gene disruption and related compositions and methods
US8105585B2 (en) 2005-08-24 2012-01-31 The Rockefeller Universtiy Ply-GBS mutant lysins
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
RU2385877C1 (en) 2005-12-22 2010-04-10 Дженентек, Инк. Recombinant production of heparin binding proteins
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2389950A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
JP2009536022A (en) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド Novel gene disruption and related compositions and methods
LT2049148T (en) * 2006-07-06 2016-11-25 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
CA2673592C (en) 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
MX2010006823A (en) 2007-12-20 2010-09-30 Xoma Technology Ltd Methods for the treatment of gout.
US20120213846A1 (en) 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
WO2010027404A2 (en) * 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulation of therapeutic polypeptides suitable for oral administration
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
WO2011047267A1 (en) 2009-10-15 2011-04-21 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
JP2013515080A (en) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド Modified bovine somatotropin polypeptides and their use
EA201290542A1 (en) 2009-12-21 2013-07-30 Амбркс, Инк. MODIFIED PORK SOMATOTROPINE POLYPEPTIDES AND THEIR APPLICATION
KR20120113265A (en) 2010-01-15 2012-10-12 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Use of vanadium compounds to accelerate bone healing
DK2536742T3 (en) 2010-02-17 2017-09-04 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
RU2012151500A (en) 2010-05-03 2014-06-10 Дженентек, Инк. COMPOSITIONS AND METHODS SUITABLE FOR REDUCING VISCOSITY OF PROTEIN-CONTAINING COMPOSITIONS
BR112012033002B1 (en) 2010-06-24 2021-10-13 Genentech, Inc AQUEOUS COMPOSITION OF MATTER, STIRRING-INDUCED AGGREGATION INHIBITION METHOD AND OXIDATION PREVENTION METHOD
EP2603232B1 (en) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
JP6149226B2 (en) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ Treatment of allodynia, hyperalgesia, spontaneous pain and phantom limb pain
JP5913326B2 (en) 2010-10-08 2016-04-27 シャンハイ クーシン バイオテック カンパニー，リミテッド Diagnostic and therapeutic use of moesin fragments
EP2624854B1 (en) 2010-10-08 2016-08-03 Shanghai Kexin Biotech Co., Ltd Moesin inhibitors and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
JP5797837B2 (en) * 2011-06-02 2015-10-21 バクスター、インターナショナル、インコーポレイテッド Recombinant furin preparation
WO2013025969A1 (en) 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
KR102259829B1 (en) 2011-10-31 2021-06-03 제넨테크, 인크. Antibody formulations
JP6320300B2 (en) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Methods for treating acne
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
CN105283196B (en) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 For generate and using conformation-specific antibody method and composition
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
EP3043824B1 (en) 2013-09-13 2022-07-06 The Scripps Research Institute Modified therapeutic agents and compositions thereof
ES2741308T3 (en) 2013-10-15 2020-02-10 Scripps Research Inst T-cell switches with chimeric antigen receptors and uses thereof
ES2845924T3 (en) 2013-10-15 2021-07-28 Scripps Research Inst T-cell switches with peptide chimeric antigen receptors and their uses
CN104623639A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of interleukin-22 dimer in preparation of drugs for treating pancreatitis
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
ES2930351T3 (en) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd An IL-22 dimer for use in the treatment of necrotizing enterocolitis
KR102613430B1 (en) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor-interacting domains and uses thereof
CN113660953A (en) 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 Compositions and methods for stabilizing protein-containing formulations
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
JP2022554187A (en) 2019-10-24 2022-12-28 ミノトール セラピューティクス インコーポレイテッド Chimeric cytokine-engineered antibodies and methods of use thereof
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022233989A1 (en) 2021-05-06 2022-11-10 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
AU2022405685A1 (en) 2021-12-10 2024-07-11 Hoba Therapeutics Aps Treatment of nociceptive pain
EP4514389A1 (en) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations

Also Published As

Publication number Publication date
BR9609741A (en) 1999-03-16
CZ9498A3 (en) 1998-06-17
KR19990028981A (en) 1999-04-15
AU715997B2 (en) 2000-02-17
CA2226523A1 (en) 1997-02-06
EP0839049A1 (en) 1998-05-06
CN1190897A (en) 1998-08-19
NO980155L (en) 1998-01-13
MX9800358A (en) 1998-07-31
JPH11509212A (en) 1999-08-17
AU6353496A (en) 1997-02-18
WO1997003692A1 (en) 1997-02-06
HUP9802287A3 (en) 2000-10-30
IL122583A0 (en) 1998-06-15
PL324379A1 (en) 1998-05-25
HUP9802287A2 (en) 1999-02-01
NO980155D0 (en) 1998-01-13

Similar Documents

Publication Publication Date Title
ZA965368B (en) A pharmaceutical formulation
ZA96124B (en) A pharmaceutical formulation
GB9519363D0 (en) Pharmaceutical formulation
EG23826A (en) Pharmaceutical formulations
AP9600883A0 (en) Pharmaceutical formulations
GB9407386D0 (en) Pharmaceutical formulation
GB9402203D0 (en) Pharmaceutical formulation
IL112521A0 (en) Pharmaceutical formulation
EP0862431A4 (en) Pharmaceutical formulation
ZA958606B (en) A pharmaceutical formulation
GB9405856D0 (en) Pharmaceutical formulation
GB9416599D0 (en) Pharmaceutical formulation
GB9523566D0 (en) Pharmaceutical formulation
ZA96526B (en) Novel pharmaceutical formulation
AU3949093A (en) A pharmaceutical formulation
ZA964372B (en) A pharmaceutical formulation
ZA965367B (en) A pharmaceutical formulation
AP9801196A0 (en) Pharmaceutical preparation
ZA96122B (en) A pharmaceutical formulation
HU9603498D0 (en) Pharmaceutical compounds
ZA96392B (en) Pharmaceutical formulations
ZA96123B (en) A pharmaceutical formulation
GB9500978D0 (en) Pharmaceutical formulations
GB9502786D0 (en) Pharmaceutical formulation
GB9525386D0 (en) Pharmaceutical formulation